What is known and objectives Tacrolimus (TAC) is a first‐line immunosuppressant which is
used to prevent transplant rejection after solid organ transplantation (SOT). However, it has …

Purpose In this study, we aimed to establish a tacrolimus population pharmacokinetic model
and better understand the drug-drug interaction between Wuzhi capsule and tacrolimus in …

Aim Wuzhi tablets are a dose‐sparing agent for tacrolimus (TAC) in China and increase the
bioavailability of TAC. The current study aimed to evaluate the pharmacokinetic interaction …

What is known and objective Tacrolimus (FK506), an effective and potent calcineurin
inhibitor, is the cornerstone of immunosuppression after kidney transplantation. Wuzhi …

Background and objectives Tacrolimus (TAC) has been increasingly used in patients with
non-transplant settings. Because of its large between-subject variability, several population …

Objectives: Wuzhi Capsule (WZC) is often administrated with tacrolimus in liver transplant
patients to reduce the toxicity of tacrolimus and relieve the financial burden of patients. We …

Background This study investigated pharmacokinetic and pharmacogenetic differences
between a modified-release once-daily formulation of tacrolimus (Tac-QD) and the original …

The present study aimed to optimize the tacrolimus initial dosing scheme in pediatric
refractory nephrotic syndrome patients based on population pharmacokinetics and …

Tacrolimus is widely used in organ transplantation to prevent rejection. However, the narrow
therapeutic window and the large inter‐and intra‐individual variability in the …

We aimed to establish a population pharmacokinetic (PK) model of tacrolimus and identify
clinical covariates, especially the genetic polymorphisms of CYP3A5, ABCB1 and POR* 28 …